Significance of Parkinson Family Genes in the Prognosis and Treatment Outcome Prediction for Lung Adenocarcinoma

Li, Yanqi; Xiao, Lü; Zhang, Jiao; Liu, Quan‐Xing; Zhou, Dong; Deng, Xu; Qiu, Yuan; Chen, Qian; Li, Man-Yuan; Yang, Guixue; Zheng, Hong; Dai, Ji‐Gang

doi:10.3389/fmolb.2021.735263

Cited by 3 publications

(1 citation statement)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this strategy, we introduced the representation of the gene expression profile using pathway scores from gene set enrichment analysis to test the ability to predict disease outcome as a domain-agnostic predictive method. Other published works proposed methods that are highly domain-dependent and require human intervention for curation [43], this method also uses GSEA but only as a post processing analysis tool. Other methods also used network-based approaches for outcome prediction with gene set enrichment [44, 45] but their focus was using the gene set enrichment as a post processing strategy to validate the findings across other biological data sources.…”

Section: Resultsmentioning

confidence: 99%

Multi-task analysis of gene expression data on cancer public datasets

Martins

2023

Preprint

View full text Add to dashboard Cite

BackgroundThere is an availability of omics and often multi-omics cancer datasets on public databases such as Gene Expression Omnibus (GEO), International Cancer Genome Consortium and The Cancer Genome Atlas Program. Most of these databases provide at least the gene expression data for the samples contained in the project. Multi-omics has been an advantageous strategy to leverage personalized medicine, but few works explore strategies to extract knowledge relying only on gene expression level for decisions on tasks such as disease outcome prediction and drug response simulation. The models and information acquired on projects based only on expression data could provide decision making background for future projects that have other level of omics data such as DNA methylation or miRNAs.ResultsWe extended previous methodologies to predict disease outcome from the combination of protein interaction networks and gene expression profiling by proposing an automated pipeline to perform the graph feature encoding and further patient networks outcome classification derived from RNA-Seq. We integrated biological networks from protein interactions and gene expression profiling to assess patient specificity combining the treatment/control ratio with the patient normalized counts of the deferentially expressed genes. We also tackled the disease outcome prediction from the gene set enrichment perspective, combining gene expression with pathway gene sets information as features source for this task. We also explored the drug response outcome perspective of the cancer disease still evaluating the relationship among gene expression profiling with single sample gene set enrichment analysis (ssGSEA), proposing a workflow to perform drug response screening according to the patient enriched pathways.ConclusionWe showed the importance of the patient network modeling for the clinical task of disease outcome prediction using graph kernel matrices strategy and showed how ssGSEA improved the prediction only using transcriptomic data combined with pathway scores. We also demonstrated a detailed screening analysis showing the impact of pathway-based gene sets and normalization types for the drug response simulation. We deployed two fully automatized Screening workflows following the FAIR principles for the disease outcome prediction and drug response simulation tasks.AvailabilityThe ScreenDOP code is available athttps://github.com/yascoma/screendopwhile the DReCaS is available athttps://github.com/YasCoMa/caliscoma_pipeline/

show abstract

Section: Resultsmentioning

confidence: 99%

Multi-task analysis of gene expression data on cancer public datasets

Martins

2023

Preprint

View full text Add to dashboard Cite

show abstract

Induro-RT mediated circRNA-sequencing (IMCR-seq) enables comprehensive profiling of full-length and long circular RNAs from low input total RNA

Unlu,

Maguire,

Guan

et al. 2024

Nucleic Acids Research

View full text Add to dashboard Cite

Circular RNA (circRNA) has recently gained attention for its emerging biological activities, relevance to disease, potential as biomarkers, and promising an alternative modality for RNA vaccines. Nevertheless, sequencing circRNAs has presented challenges. In this context, we introduce a novel circRNA sequencing method called Induro-RT mediated circRNA-sequencing (IMCR-seq), which relies on a group II intron reverse transcriptase with robust rolling circle reverse transcription activity. The IMCR-seq protocol eliminates the need for conventional circRNA enrichment methods such as rRNA depletion and RNaseR digestion yet achieved the highest circRNA enrichment and detected 6–1000 times more circRNAs for the benchmarked human samples compared to other methods. IMCR-seq is applicable to any organism, capable of detecting circRNAs of longer than 7000 nucleotides, and is effective on samples as small as 10 ng of total RNA. These enhancements render IMCR-seq suitable for clinical samples, including disease tissues and liquid biopsies. We demonstrated the clinical relevance of IMCR-seq by detecting cancer-specific circRNAs as potential biomarkers from IMCR-seq results on lung tumor tissues together with blood plasma samples from both a healthy individual and a lung cancer patient. In summary, IMCR-seq presents an efficient and versatile circRNA sequencing method with high potential for research and clinical applications.

show abstract

Construction and Validation of a Seven-Gene Signature for Predicting Prognosis and treatment response of Melanoma Based on Parkinson's Disease Family Genes

He,

Zhang,

et al. 2024

Preprint

View full text Add to dashboard Cite

Parkinson's disease (PD) patients generally have a lower cancer risk, except for an increased melanoma risk, suggesting a link between PD genes and melanoma development.However, comprehensive research on the expression and function of the Parkinson's gene family in melanoma is currently lacking. Here, this study aimed to explore the expression of Parkinson's genes in melanoma and their predictive value for prognosis and treatment response will aid in the development of new diagnostic and therapeutic markers for melanoma. Using LASSO regression analysis, we obtained a seven Parkinson's genes signature melanoma prognosis model, including LRRK2, UCHL1, SNCA, VPS13C, SPR, EIF4G1, and FBXO7. Subsequently, internal verification with TCGA cohort and external verification with GEO cohort showed that the seven-gene prognostic model could effectively predict the prognosis for patients with melanoma. Paitents with high risk score had worse overall survival than those with high risk score. The signaling pathways related to anti-tumor immunity, such as interferon α/γ, were significantly activated in the low-risk group. Cancer-related signaling pathways are mainly enriched in high-risk group, such as mTOR, WNT/β-catenin, and Notch pathways. Moreover, low-risk melanoma patients have a higher infiltration of CD8+ T, cytotoxic, and Th1 cells within the tissue as compared with high-risk patients. Melanom patients in the low-risk group had a higher response rate and longer survival after PD-1 treatment, and were more sensitive to drug treatment, such as Nilotinib. We have successfully constructed a 7-gene signature based on Parkinson's disease familial genes, which can efficiently predict the prognosis of melanoma and treatment response.

show abstract

Significance of Parkinson Family Genes in the Prognosis and Treatment Outcome Prediction for Lung Adenocarcinoma

Cited by 3 publications

References 52 publications

Multi-task analysis of gene expression data on cancer public datasets

Multi-task analysis of gene expression data on cancer public datasets

Induro-RT mediated circRNA-sequencing (IMCR-seq) enables comprehensive profiling of full-length and long circular RNAs from low input total RNA

Construction and Validation of a Seven-Gene Signature for Predicting Prognosis and treatment response of Melanoma Based on Parkinson's Disease Family Genes

Contact Info

Product

Resources

About